pital
Welcome to the 32nd Annual Enterprise Awards
Celebrated for championing regional excellence, the Enterprise Awards – now in its 32nd year – offers a stage to spotlight trailblazing achievements across the region’s technology, life sciences, and healthcare landscapes.
Highlight your groundbreaking innovations, impactful deals, or salute the standout feats of your colleagues. Submit your application(s) and celebrate the brilliance our sectors have to offer. Winners will join a prestigious pool of previous awardees, like Spark Therapeutics, AscellaHealth, Crossbeam, Capgemini, Tendo, and many more!
NAVIGATION
PACT’s Enterprise Awards is a dazzling celebration of groundbreaking innovation in technology, life sciences, and investment in the Greater Philadelphia Region. In a brief awards program that transcends the ordinary, we honor the trailblazing Finalists who have redefined the future. Brace yourselves for the unveiling of the Winners – the visionaries who have set new benchmarks in excellence – and then join your fellow attendees and industry leaders for an evening of connecting over delicious drinks and tasty treats in a fun outdoor reception.
See the photos from 2024’s awards ceremony and reception.
Awards Criteria
To nominate a deserving company (whether your own or those in your network/portfolio/community), please follow this link and complete the requested information.
The deadline for nominations is Monday, December 16th.
Please click below to see the criteria for each of the eight prestigious Enterprise Awards.
Technology Startup
A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.
Criteria:
- Company should have been founded, launched meaningful operations, or pivoted to current strategic focus at some point in the period between January 1, 2021, and December 31, 2024.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
Key Considerations:
- Product or service innovation including market need or assessment.
- Potential for significant growth.
- The management team and its ability and record of achieving success.
- A demonstration of success such as significant milestones, raising capital, and revenue.
Technology Emerging
A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.
Criteria:
- Company must have been in operation before January 1, 2021.
- Revenues must be less than $50 million. *If revenues are projected to exceed $50m in 2024, please complete the Technology Company application.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
Key Considerations:
- Product or service innovation, including proprietary technology or other advantage.
- Company milestones including strategic decisions made by management that led to growth in revenues and/or earnings.
- Strength of management team including ability to raise capital.
- Demonstration of a sustainable and scalable business model.
Technology Company of the Year
A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.
Criteria:
- Company with more than $50 million in revenues projected for the current fiscal year.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
Key Considerations:
- Leadership and product and/or service innovation in an industry or market.
- Significant company milestones including financial accomplishments.
- The Company’s connection and commitments to the Greater Philadelphia region through community and industry involvement.
Technology Investment Deal
Criteria:
- Company with more than $50 million in revenues projected for the current fiscal year.
- Deal must have been fully executed between November 1, 2023, and October 31, 2024.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees and consultants must be based in the region.
- Events that qualify for this category include: IPO; Capital Raise; Buy-Side Merger & Acquisition Transaction; Sell-Side Merger & Acquisition Transaction
Key Considerations:
- Realized returns for the investors and management.
- EBITDA margin and revenue growth.
- Strategic considerations of the deal (e.g. commercial strategy, innovation, and contribution to market development.
- Company performance prior to transaction.
- How the sale or purchase impacted the broader industry(s) of the buyer and/or seller.
Life Sciences & Healthcare Startup
Criteria:
- Company should have been founded, launched meaningful operations, or pivoted to current strategic focus at some point between January 1, 2021, and December 31, 2024.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
Key Considerations:
- Product innovation including unmet market need and how that is uniquely addressed by your product/service.
- The management team and its ability and record of achieving success.
- Provide demonstration of success (e.g., significant milestones, raising capital, revenue, etc.).
- Describe the R&D investment strategy.
- What did the company do to overcome challenges in financing, development, or commercialization?
Life Sciences and Healthcare Emerging
Criteria:
- Company must have been in operation beginning on January 1, 2021. The Company should have no more than 8 years of operating results since its founding.
- Must have sales, grants, or licensing fees.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
Key Considerations:
- Describe product or service, including proprietary applications or other competitive advantage.
- The impact on the clinical problem this product or innovation is trying to solve (e.g. saving a hospital money on a procedure, making a clinician more productive, etc.).
- Company milestones including strategic decisions made by the management team that led to growth in revenues and/or earnings, corporate collaborations, or license deals (e.g. ability to raise capital, strategy to achieve breakeven, ability to realize high gross margins, etc.).
Life Sciences & Healthcare Company of the Year
Criteria:
- Company must have at least four years of operating results in industry segments such as specialty pharmaceuticals, biotechnology, medical devices, instrumentation, therapeutics, diagnostics, health tech, etc.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
Key Considerations:
- Company should demonstrate the impact of a proprietary product to the patient and/or clinician or research and development of an innovative product and its potential impact on the market.
- Company should demonstrate its ability to raise capital; achieve success in its development strategy and clinical pathway; commercialize and generate revenue.
- Describe any significant events, e.g. product discovery, drug registration, commercial launch, an exit, an increase in sales, etc. that occurred in 2022.
- What did the company do to overcome challenges in financing, development, or commercialization?
Life Sciences & Healthcare Startup
Criteria:
- Company should have been founded, launched meaningful operations, or pivoted to current strategic focus at some point between January 1, 2021, and December 31, 2024.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.
Key Considerations:
- Product innovation including unmet market need and how that is uniquely addressed by your product/service.
- The management team and its ability and record of achieving success.
- Provide demonstration of success (e.g., significant milestones, raising capital, revenue, etc.).
- Describe the R&D investment strategy.
- What did the company do to overcome challenges in financing, development, or commercialization?
Life Sciences & Healthcare Investment Deal
Criteria:
- Deal must have been fully executed between November 1, 2023, and October 31, 2024.
- Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees and consultants must be based in the region.
- Events that qualify for this category include: IPO; Capital Raise; Buy-Side Merger & Acquisition Transaction; Sell-Side Merger & Acquisition Transaction
Key Considerations:
- Realized returns for the investors and management.
- EBITDA margin and revenue growth.
- Strategic considerations of the deal (e.g. commercial strategy, innovation, and contribution to market development.
- Company performance prior to transaction.
- How the sale or purchase impacted the broader industry(s) of the buyer and/or seller.
2025 Sponsors
Title Sponsor
Judging Partner
AWARD SPONSORS
EVENT SPONSORS
Judges
LEAD JUDGE
Rick Riegel
Chairman
ActiGraph and Deerfield
Technology Judging Panel Oversight
Andrew Cherry
Partner
KPMG
Life Sciences & Healthcare Judging Panel Oversight
Jennifer Strong
Partner
KPMG
Tom Koncsics
Partner
KPMG
Technology Judges
Michael Bachman, Head of Research – Principal Technologist, Boomi
Joe Biancaniello, Vice President, JP Morgan
Amy (Wang) Branson, Vice President, NewSpring Capital
Kyle Carlson, Venture Portfolio and Commercialization Manager, SEI
Elaine Cheong, Senior Vice President, Bank of America
Donna Dorozinsky, Founder & CEO, Just in Time GCP
Sean Dowling, Partner, Osage Partners
Laura Plunkett, Executive Director – Startup Engagement, Comcast NBCUniversal LIFTLabs
Tiffanie Stanard, Founder & CEO, Stimulus
Life Sciences & Healthcare Judges
Gerianne DiPiano, Chief Executive Officer, FemmePharma
Tiara Durham, Director of New Ventures, University City Science Center
Audrey Greenberg, Founder, Center for Breakthrough Medicines
Karen Griffith Gryga, COO, Biomeme
Matthew Reber, Partner, 1315 Capital
Bill Rhoda, General Partner & Chief Innovation Officer, Runway Healthcare